

III. REMARKS

Claims 1-19 are pending. Claims 1-12 have been amended to include the word “and” in order to provide proper Markush language. Claim 4 has further been amended to include the phrase “or a pharmaceutically acceptable salt thereof” in place of “and the pharmaceutically acceptable salts thereof” to mirror the alternative language in claim 1. Claim 8 has been further amended to remove the phrase “and the pharmaceutically acceptable salts thereof” to avoid redundancy from the preamble of that claim. Claim 12 has been further amended to include the phrase “or a pharmaceutically acceptable salt thereof” in place of “and the pharmaceutically acceptable salts thereof” to mirror the alternative language in claim 9. Claim 13 has been amended to remove the phrase “including restenosis.” Claim 14 has been amended to remove the phrases “including tumor angiogenesis” and “including restenosis”. Claim 15 has been amended to remove the phrase “, including a human,”.

Claim Objections

Objection of Claims 13-15

A. Claims 13 and 15 have been amended to remove the use of the language “including”

On page 2 of the Office Action, the Office points out that the phrase “including” is used in claims 13-15. Applicants have amended the claims to remove the use of the phrase “including”.

It is therefore submitted that Claims 1-16 are in condition for allowance. If the Office has any further comments or concerns, the Examiner is welcome to contact Applicants at the number below.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Rachel A. Polster".

Rachel A. Polster

Registration No. 47,004

Telephone: 314-274-7354

Pfizer Corporation
Global Patent Department
P.O. Box 1027
St. Louis, MO 63006